Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level?

Abstract

The antifolate drug methotrexate (MTX) was introduced into clinical practice about 60 years ago and remains an important component of different acute lymphoblastic leukemia (ALL) treatment protocols. It acts by inhibiting several enzymes in the folate pathway, thereby resulting in the disruption of folate homeostasis. To date, treatment regimens have not… (More)
DOI: 10.1007/s00228-013-1623-4

Topics

3 Figures and Tables

Slides referencing similar topics